Damiano Magrì1, Cristina Banfi2, Antonello Maruotti3, Stefania Farina2, Carlo Vignati2, Elisabetta Salvioni2, Marco Morosin4, Maura Brioschi2, Stefania Ghilardi2, Elena Tremoli2, Piergiuseppe Agostoni5. 1. Department of Clinical and Molecular Medicine, University "La Sapienza", Rome, Italy. 2. Centro Cardiologico Monzino, IRCCS, University of Milan, Italy. 3. Southampton Statistical Sciences Research Institute, School of Mathematics, University of Southampton, United Kingdom; Department of Public Institutions, Economy and Society, University "Roma Tre", Rome, Italy. 4. Centro Cardiologico Monzino, IRCCS, University of Milan, Italy; Cardiovascular Dept., "Ospedali Riuniti", Trieste, Postgraduate School of Cardiovascular Sciences, University of Trieste, Italy. 5. Centro Cardiologico Monzino, IRCCS, University of Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Italy. Electronic address: piergiuseppe.agostoni@unimi.it.
Abstract
BACKGROUND: Gas exchange abnormalities are part of the heart failure (HF) syndrome and growing interest raised on possible biomarkers of alveolar-capillary unit damage. The present pilot single-center study sought to investigate the prognostic values of circulating surfactant protein type B (SP-B) in a cohort of systolic HF patients. METHODS: One hundred and fifty-one HF stable outpatients and 37 healthy subjects underwent a full clinical assessment, including pulmonary function and lung diffusion for carbon monoxide (DLco), maximal cardiopulmonary exercise test and measurements for both circulating immature and mature forms of SP-B. Study end-points were hospitalization due to HF worsening and cardiovascular mortality. RESULTS: Immature SP-B, but not the mature form, was significantly higher in HF patients than in controls and was independently related to DLco, peak oxygen uptake and ventilatory efficiency. During the follow-up (median: 995 days; interquartile range: 739-1247 days), 97 patients experimented at least one HF hospitalization and 9 died for cardiovascular causes. At univariate analysis immature SP-B levels were significantly related to both cardiovascular death (p=0.033) and HF hospitalization (p<0.001). At multivariate analysis, immature SP-B levels remained independently associated to HF hospitalization (hazard ratio: 2.304; 95% confidence interval 1.858-3.019; p<0.001). CONCLUSIONS: Present data confirm a strong relationship between circulating immature SP-B levels, gas exchange abnormalities and exercise limitations in stable HF as well as they are consistent with the use of immature SP-B in HF clinical risk assessment. Larger prospective studies are needed to confirm its prognostic role as well as to evaluate whether immature SP-B plasma concentration varies in response to specific treatment.
BACKGROUND:Gas exchange abnormalities are part of the heart failure (HF) syndrome and growing interest raised on possible biomarkers of alveolar-capillary unit damage. The present pilot single-center study sought to investigate the prognostic values of circulating surfactant protein type B (SP-B) in a cohort of systolic HFpatients. METHODS: One hundred and fifty-one HF stable outpatients and 37 healthy subjects underwent a full clinical assessment, including pulmonary function and lung diffusion for carbon monoxide (DLco), maximal cardiopulmonary exercise test and measurements for both circulating immature and mature forms of SP-B. Study end-points were hospitalization due to HF worsening and cardiovascular mortality. RESULTS: Immature SP-B, but not the mature form, was significantly higher in HF patients than in controls and was independently related to DLco, peak oxygen uptake and ventilatory efficiency. During the follow-up (median: 995 days; interquartile range: 739-1247 days), 97 patients experimented at least one HF hospitalization and 9 died for cardiovascular causes. At univariate analysis immature SP-B levels were significantly related to both cardiovascular death (p=0.033) and HF hospitalization (p<0.001). At multivariate analysis, immature SP-B levels remained independently associated to HF hospitalization (hazard ratio: 2.304; 95% confidence interval 1.858-3.019; p<0.001). CONCLUSIONS: Present data confirm a strong relationship between circulating immature SP-B levels, gas exchange abnormalities and exercise limitations in stable HF as well as they are consistent with the use of immature SP-B in HF clinical risk assessment. Larger prospective studies are needed to confirm its prognostic role as well as to evaluate whether immature SP-B plasma concentration varies in response to specific treatment.
Authors: Baohai Shao; Janet K Snell-Bergeon; Laura L Pyle; Katie E Thomas; Ian H de Boer; Vishal Kothari; Jere Segrest; William S Davidson; Karin E Bornfeldt; Jay W Heinecke Journal: J Lipid Res Date: 2022-03-14 Impact factor: 6.676